

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Original) A method for resensitizing non P-gp/non MRP multiple drug resistant cancer cells to treatment with chemotherapeutic agents to which cancer cells have developed resistance comprising administration of an effective amount of a chemosensitizing reversal agent and a chemotherapeutic agent.
3. (Original) The method according to claim 2 wherein the chemosensitizing reversal agent is selected from the group consisting of fumitremorgin A, fumitremorgin B and fumitremorgin C.
4. (Original) The method according to claim 2 wherein the chemotherapeutic agent used is one to which the cancer cells are resistant.
5. (Original) The method according to claim 2 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin and topotecan.
6. (Original) The method of claim 3 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.
7. (Canceled)
8. (Original) A method for resensitizing BCRP-mediated multiple drug resistant cancer cells to treatment with chemotherapeutic agents to which cancer cells have developed resistance comprising administration of an effective amount of a chemosensitizing reversal agent and a chemotherapeutic agent.

9. (Original) The method according to claim 8 wherein the chemotherapeutic agent used is one to which the cancer cells are resistant.

10. (Original) The method according to claim 9 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin, and topotecan.

11. (Original) The method according to claim 8 wherein the chemosensitizing reversal agent is selected from the group consisting of fumitremorgin A, fumitremorgin B and fumitremorgin C.

12. (Original) The method according to claim 11 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.

13-28. (Canceled)

29. (Original) A method of reversing BCRP or other non P-gp/non MRP resistance to chemotherapeutic agents in a mammal which comprises administration of an effective amount of a chemosensitizing reversal agent to a mammal in need thereof having a BCRP or other non-P-gp/non MRP resistant cancer.

30. (Original) The method according to claim 29 wherein the chemotherapeutic agent used is one to which the cancer cells are resistant.

31. (Original) The method according to claim 29 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin, and topotecan.

32. (Original) The method according to claim 29 wherein the chemosensitizing reversal agent is selected from the group consisting of fumitremorgin A, fumitremorgin B and fumitremorgin C.

33. (Original) The method according to claim 32 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.

34-38. (Canceled)

39. (Original) The method of inhibiting efflux of a chemotherapeutic agent in a mammal in need thereof which comprises administration of an effective amount of a chemosensitizing reversal agent and a chemotherapeutic agent to which the cancer is resistant.

40. (Original) The method according to claim 39 wherein the chemotherapeutic agent used is one to which the cancer cells show resistance to the BCRP or other non P-gp/MRP-mediated phenotype.


41. (Original) The method according to claim 39 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin, and topotecan.

42. (Original) The method according to claim 39 wherein the chemosensitizing reversal agent is selected from the group consisting of fumitremorgin A, fumitremorgin B and fumitremorgin C.

43. (Original) The method according to claim 42 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.

44-54. (Canceled)

55. (Previously Presented) The method according to claim 2 wherein the chemosensitizing reversal agent is selected from a compound having the Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v— or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or




R⁸ is selected from alkyl of 1 to 10 carbon atoms, —(CH₂)_mCO₂H,



or a pharmaceutically acceptable salt thereof.

56. (Previously Presented) The method according to claim 8 wherein the chemosensitizing reversal agent is selected from a compound having the Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v— or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or




R⁸ is selected from alkyl of 1 to 10 carbon atoms, —(CH₂)_mCO₂H,



or a pharmaceutically acceptable salt thereof.

57-59. (Canceled)

60. (Previously Presented) A method according to claim 29 wherein the chemosensitizing reversal agent is selected from a compound having the Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v— or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or



R⁸ is selected from alkyl of 1 to 10 carbon atoms, —(CH₂)_mCO₂H,




or a pharmaceutically acceptable salt thereof.

61. (Canceled)

62. (Previously Presented) A method according to claim 39 wherein the chemosensitizing

reversal agent is selected from a compound having the Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v— or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or



R⁸ is selected from alkyl of 1 to 10 carbon atoms, -(CH₂)_mCO₂H,



or a pharmaceutically acceptable salt thereof.

63. (Canceled)